FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccine
The Food and Drug Administration has flagged Guillain-Barre syndrome, a rare neurological condition, as a potential risk for Pfizer’s respiratory syncytial virus vaccine. Two people in their 60s who received the shot were